Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-21
2011-06-21
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S368000
Reexamination Certificate
active
07964604
ABSTRACT:
The present disclosure provides novel pharmaceutical dosage forms such as a maintenance treatment dose and methods for making the same, and methods for using said compounds and maintenance treatment doses to treat and prevent diseases and/or disorders.
REFERENCES:
patent: 7405216 (2008-07-01), Eijgendaal et al.
patent: 7423040 (2008-09-01), Eijgendaal et al.
patent: 7435738 (2008-10-01), Eijgendaal et al.
patent: 2004/0077631 (2004-04-01), van Aar et al.
patent: 2005/0234389 (2005-10-01), Bouwstra et al.
patent: 2009/0068290 (2009-03-01), Bourin et al.
patent: 0 908 458 (1999-04-01), None
patent: 0 189 612 (2006-08-01), None
patent: WO 97/36893 (1997-10-01), None
patent: WO 00/29397 (2000-05-01), None
patent: WO 01/74365 (2001-10-01), None
patent: WO 02/066449 (2002-08-01), None
patent: WO 2006/032202 (2006-03-01), None
patent: WO 2006/087369 (2006-08-01), None
patent: WO 2007/023141 (2007-03-01), None
“Bifeprunox—Atypical Antipsychotic Drug,” Drug Development Technology, pp. 1-3, 2007, www.drugdevelopment-technology.com/projects/bifeprunox/.
“Solvay Announces New Drug Plans for Schizophrenia,” Schizophernia Daily New Blog, pp. 1-4 (2004), www.schizophrenia.com/sznews/archives/000573.html.
(XP-001061442) Johnston, L.C. et al., “134P: The Novel Dopamine D2 Receptor Partial Agonist, SLV-308, Reverses Motor Disability in MPTO-Lesioned Common Marmosets (Callithrixjacchus),” British Journal of Pharmacology, vol. 133, No. 2 (2001).
(XP-001061489) Feenstra, R. et al., “Antiparkinsonian Antidepressant Anxiolytic Dopamine D2 Partial Agonist 5-HT1A Agonist,” Drugs of the Future, vol. 26, No. 2, 2001, pp. 128-132.
(XP-001197381) McCreary, et al., “SLV308: A Novel Antiparkinsonian Agent With Antidepressant and Anxiolytic Efficacy,” Abstracts of the Society for Neuroscience (2001).
(XP-002412435) Hesselink, M. et al., “308, A Molecule Combining Potent Partial Dopamine b2 Receptor Agonism with Serotonin 5-HT1A Receptor Agonism: In vitro and in vivo neuro-chemistry,” 31st Annual Meeting of the Society for Neuroscience (2001).
(XP-002412436) Johnston, L.C. et al., “SLV308: Antiparkinsonian Effects in the MPTP-Treated Common Marmoset (Callithrix jacchus),” 31st Annual Meeting of the Society for Neuroscience (2001).
(XP-002412438) Long Act Sustained-Relase Formulations for Treating Parkinson's Disease, Comprise a Dopamine Receptor Agonist and Biodegradable Pharmaceutical Polymer Excipient for Injection Transplant, Corresponds to WO 2006/032202.
(XP-008033520) Wolf, William A., “SLV-308 Solvay,” Current Opinion in Investigational Drugs, vol. 4, No. 7, 2003, pp. 878-882.
Allen, et al. “A Review of Clinical and Pathophysiologic Features,” Journal of Clinical Neurophysiology, vol. 18, No. 2, 2001, pp. 128-147.
Allen, et al., “Augmentation of the Restless Legs Syndrome With Carbidopa/Levedopa,” Sleep, vol. 19, No. 3, 1996, pp. 205-213.
Bara-Jimenez et al., “Effects of Serotonin 5-HT1A Agonist in Advanced Parkinson's Disease,” Movement Disorders, vol. 20, No. 8, 2005, pp. 932-936.
Bennett, et al., “Pramipexole—A new dopamine agonist for the treatment of Parkinson's Disease,” Journal of Neurological Sciences, vol. 163, 1999, pp. 25-31.
Berendsen, et al., “Selective Activation of 5HT1A Receptors Induces Lower Lip Retraction in the Rat,” Pharmacology Biochemistry & Behavior, vol. 33, pp. 821-827, 1989.
Bibbiani, et al., “Serotonin 5-HT1A Agonist Improves Motor Complications in Rodent and Primate Parkinsonian Models,” Neurology, vol. 57, 2001, pp. 1829-1834.
Bickel, M.H., “The Pharmacology and Biochemistry of N-Oxides,” Pharmacological Reviews, vol. 21, No. 4, pp. 325-355, 1969.
Blandini, et al., “Functional Changes of the Basal Ganglia Circuitry in Parkinson's Disease,” Progress in Neurobiology, vol. 62, 2000, pp. 63-88.
Chesson, et al., “Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder,” Sleep, vol. 22, No. 7, 1999, pp. 961-968.
Christoffersen, et al., “Reversal of Haloperiodol-Induced Extrapyramidal Side Effects in Cebus Monkeys by 8-Hydroxy-2-(di-n-propylamino)tetralin and Enantiomers,” Neuropsychopharmacology, vol. 18, No. 5, 1998, pp. 399-402.
Costall et al., “Differential actions of typical and atypical neuroleptic agents on two behavioural effects of apomorphine in the mouse,” Proceedings of the B.P.S., pp. 381-381, 1978.
Creese et al., “3H-Spiroperidol Labels Dopamine Receptors in Pituitary and Brain,” European Journal of Pharmacology, 46, pp. 377-381, 1977.
Earley, et al., “Movements During Sleep: Pergolide and Carbidopa/Levedopa Treatment of the Restless Legs Syndrome and Periodic Leg Movements in Sleep in a Consecutive Series of Patients,” Sleep, vol. 19, No. 10, 1996, pp. 801-810.
Feenstra, et al., “New 1-Aryl-4-(biarylmethylene) piperazines as Potential Atypical Antipsychotics Sharing Dopamine Dz-Receptor and Serotonin 5-HT1A-Receptor Affinities,” Bioorganic & Medicinal Chemistry Letters, vol. 11, 2001, pp. 2345-2349.
Feenstra, et al., “New Approaches for Psychosis Treatment: Design, Synthesis and SAR of Ligands Binding to Dopamine-D2- and Serotonin 5-HT1A Receptors,” Drugs of the Future, vol. 27, Suppl. A, p. 226 (P237), XVIIth International Symposium on Medicinal Chemistry (2002).
Fleischhacker, “Clozapine: A Comparison With Other Novel Antipsychotics,” J. Clin Psychiatry, vol. 60, No. 12, 1999, pp. 30-34.
Gozlan, et al., “Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT,” Nature, vol. 305, pp. 140-142, 1983.
Haleblian et al., “Pharmaceutical Applications of Polymorphism,” Journal of Pharmaceuticals Sciences, vol. 58, No. 8, 1969, pp. 911-929.
Hening, et al., “Dyskinesias While Awake and Periodice Movements in Sleep in Restless Legs Syndrome: Treatment with Opioids,” Neurology, vol. 36, 1986, pp. 1363-1366.
Hening, et al., “The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder,” Sleep, vol. 22, No. 7, 1999, pp. 970-999.
Hesselink, M.B., et al., “P2151” “DU127090, SLV308 and SLV318: Characterization of a Chemically Related Class of Partial Dopamine Agonists with Varying Degrees of 5-HT1A Agonism,” EFNS European Journal of Neurology, vol. 10 (Suppl. 1), 2003, pp. 125-204.
Hornykiewicz, Oleh, “Dopamine (3-Hydroxytyramine) and Brain Function,” Pharmaceutical Reviews, vol. 18, No. 2, 1966, pp. 925-964.
Jankovic, “Natural Course and Limitations of Levodopa Therapy,” Neurology, vol. 43, No. 2, Supplement 1, 1993, pp. S1-14 thru S1-17.
Jenner, Peter, “Pharmacology of Dopamine Agonists in the Treatment of Parkinson's Disease,” Neurology vol. 58 (Suppl. 1), 2002, pp. S1-S8.
Johnston, et al., P2158, “Association between Instrinsic Activity and the Antiparkinsonian Effects of a Novel Dopamine D2 Agonist series in the 1-methyl-4phenyl-1,2,3,6-tetrahydeopyridine Treated Primate Model of Parkinson's Disease,” EFNS European Journal of Neurology, vol. 10 (Suppl. 1), 2003, pp. 169-170.
Jost, et al., “Efficacy and tolerability of Stalevo® in Patients with Parkinson's Disease Experiencing Wearing-off,” Akt Neurol, vol. 32, Supplement 6, 2005, pp. S318-S325 (XP009074453), Abstract.
Kannari, et al., “Tandospirone Citrate, selective 5-HT1A Agonist, Alleviates L-DOPA-Induced Dyskinesia in Patients with Parkinson's Disease,” Brain and Nerve, vol. 54, No. 2, 2002, pp. 133-137, Abstract.
Kim, et al., “Risperidone Dosing Pattern and Clinical Outcome in Psychosis: An Analysis of 1713 Cases,” J. Clin Psychiatry, vol. 66, No. 7, 2005, pp. 887-893.
Lange, et al., “Terguride Stimulates Locomotor Activity at 2 Months but Not 10 Months after 1-methyl-4-phenyl-1,2,3,6-tetrahy
Boon Caroline
Bruins Nico
Christensen Ellen Bech
De Vries Michiel H.
Eijgendaal Irene
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Sackey Ebenezer
Solvay Pharmaceuticals B.V.
Wilson James O
LandOfFree
Bifeprunox mesylate maintenance dose compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bifeprunox mesylate maintenance dose compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifeprunox mesylate maintenance dose compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2703951